Complications of Coronary Artery Interventions: Overview | SpringerLink
Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks - ScienceDirect
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study | Semantic Scholar
Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention: Insights From the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary ...
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study | Semantic Scholar
Atrial Fibrillation on Vitamin K Antagonist Oral Anticoagulant Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Acute Myocardial Infarction | SpringerLink
Cardiovascular Medicine - Current trends in dual antiplatelet therapy: a 2017 update
Health Economic Evaluation of an Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Compared to a Thin, Durable-Polymer Everolimus-Eluting Stent - ScienceDirect
Impact of Intra-procedural Stent Thrombosis during Percutaneous Coronary Intervention: Insights from the CHAMPION PHOENIX Trial. | Request PDF
The evolution of antiplatelet therapy in cardiovascular disease | Nature Reviews Cardiology
Rapamune (Sirolimus) Market Share, Size 2020 By Industry Future Demand, Global Research, Top Leading Players, Developing Trends, Region Forecast To 2026 | News Break
PDF) Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention: Results From CHAMPION PHOENIX
Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention: Insights From the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary ...
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study - Tamez - 2018 - Catheterization and Cardiovascular Interventions - Wiley Online Library
Antiplatelet Drugs in the Management of Coronary Artery Disease - ScienceDirect
Acute myocardial infarction - The Lancet
![Full text] Prevention of stent thrombosis: challenges and solutions | VHRM](https://www.dovepress.com/cr_data/article_fulltext/s43000/43357/img/Table4.jpg "Full text] Prevention of stent thrombosis: challenges and solutions | VHRM")
Full text] Prevention of stent thrombosis: challenges and solutions | VHRM
PDF) The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: A clinical conundrum
Study flow diagram. | Download Scientific Diagram
Intra-Procedural Stent Thrombosis: A New Risk Factor for Adverse Outcomes in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes | JACC: Cardiovascular Interventions
Usefulness of Intravascular Ultrasound for Predicting Risk of Intraprocedural Stent Thrombosis. | Semantic Scholar
2014 ESC/EACTS Guidelines on myocardial revascularization – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open science hub.
Novel Antiplatelet Therapies for Atherothrombotic Diseases | Arteriosclerosis, Thrombosis, and Vascular Biology
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study | Semantic Scholar
TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics – The CHAMPION PHOENIX Trial | tctmd.com
Cangrelor for treatment during percutaneous coronary intervention | Future Cardiology
